Transcript AstraZeneca`s R&D site in the Göteborg region

The AstraZeneca Site in the Göteborg Region
The Headquarter for Cardiovascular and
Gastrointestinal Research
Martin Nicklasson
Executive Vice President, AstraZeneca plc
CEO & President, AstraZeneca AB
2005-11-10 M Nicklasson
1
AstraZeneca in Sweden
Key figures
Sales in Sweden
– percent of Group sales
– including parallel import
1.4%
2.9 billion SEK
Market share
8.4%
Rank in Swedish pharmaceutical market
No. 2
Swedish export
Share of Swedish net export
Swedish licensing income
2005-11-10 M Nicklasson
2 billion SEK
39 billion SEK
20%
8 billion SEK
No. of Swedish shareholders
161,000
Share of Swedish ownership
(of total No. of shares)
22.7%
2
Mölndal
2005-11-10 M Nicklasson
3
R&D units
Montreal
Alderley
Charnwood
Mölndal
Södertälje
Lund
Osaka
Wilmington
Boston
2005-11-10 M Nicklasson
Bangalore
Reims
4
Brisbane
AZ Cardiovascular Drug Discovery
Research Areas at the Mölndal site
•
Metabolism:
• Obesity
• Dyslipidemia
• Diabetes
•
Atherosclerosis
• Thromboembolism
• Cardiology
2005-11-10 M Nicklasson
5
AZ Gastrointestinal Drug Discovery
Research Areas at the Mölndal site
•
Gastroesophageal Erosive Reflux Disease
•
Functional Gastrointestinal Disorders
•
Inflammatory Bowel Disease
2005-11-10 M Nicklasson
6
Key factors driving collaborations
• Access to broader basic knowledge as base for
new projects or specific competence for key
technologies
• Create networks to increase the recruitment base
• Access to unique expertise that can’t or shouldn’t
be built in-house
• Facilitate establishment of high quality research
groups within areas of long term strategic
importance
2005-11-10 M Nicklasson
7
Elements of innovation in Drug Discovery
at AstraZeneca
1. Presence in a global network of research sites on major
continents within AstraZeneca
2. Effective in-house drug discovery and research informatics
processes (knowledge transfer)
3. Mechanisms for learning (adoptation of best practices)
4. Network of important academic and biotechnology partners
5. Effective management of research at several sites and
continents
2005-11-10 M Nicklasson
8
How important are the links to academic
research in the Gothenburg region?
•
•
Current AstraZeneca collaboration value to
Gothenburg University amounts to a total of
7.34 m$
The relations with Academia have in the past
contributed to significant discoveries (Losec®,
Nexium®, Seloken®)
2005-11-10 M Nicklasson
9
Areas of collaboration in drug development – AstraZeneca and Gothenburg
University
 Epidemiology – ”get to know the disease”
 Mechanistical research – ”get to know how to
test Proof of Principle for a new substance”
 Large scale clinical trials – landmark studies
with potential to change routine therapy
 General consultancy – expert advice at any
stage of drug development
2005-11-10 M Nicklasson
10
Specific examples of collaboration
Epidemiology
 Hypertension, myocardial infarction, heart
failure
 Metabolic diseases
– Diabetes
– Obesity
 Acid secretion related to GI diseases
2005-11-10 M Nicklasson
11
Specific examples of collaboration
Mechanistical research




GI laboratory
Metabolic laboratory
Cardiovascular clinical physiology laboratory
Arrhythmia laboratory
Development of sophisticated techniques to
measure treatment effects
2005-11-10 M Nicklasson
12
Specific examples of collaboration
Large scale clinical trials






Hypertension (e.g. HAPPHY, MAPHY, HOT)
Heart failure (e.g. MERIT, CHARM)
Myocardial infarction (GMT, MIAMI)
Lipid disorders (CORONA)
Thrombosis related disorders (METHRO)
Acid secretion related GI disorders
University scientists in Scientific Steering Committees.
Results of studies which have (or will) shift treatment
guidelines for the disease.
2005-11-10 M Nicklasson
13
Industry – academia collaboration
 Prerequisites
– Scientists on both sides work together with Trust and
Respect
 This requires
– Same competence level
– Personal chemistry OK
– Genuine wish to collaborate
 N.B.
– Need to be in frontline of research on a worldwide basis
– Industry needs to seek collaboration with “the best” to be
competitive
2005-11-10 M Nicklasson
14
Key factors for AstraZeneca’s continued
presence in the region
AstraZeneca captures biomedical innovations globally through
its research presence at different continents.
Critical for the locations in Gothenburg is:
• The proximity to and the ability of the local universities to develop world class basic biomedical and chemical research
• The ability of the universities to educate high quality students
• To make clear and public statements in important ethical issues, such as:
- Positive attitude and support to animal experimentation
- Stem cell research
• Providing for excellent infrastructure facilities employment of scientists coming from abroad:
- International schools of high quality
The focus of the region to applied/translational research is for AstraZeneca of lesser
importance
2005-11-10 M Nicklasson
15
Conclusions
• Academia and Biotech collaborations play and will play a very
important part in AstraZeneca
Technology integration
New Drug Project generation
• Academia research will always be a major source of innovation for
pharma industry
• True partnership can only thrive when there is a natural interest
between scientists
2005-11-10 M Nicklasson
16